After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...

The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

Sun Pharma has introduced LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for severe alopecia areata after settling a patent dispute with Incyte. Approved by the FDA and backed by strong clinical ...

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...